These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 21763970

  • 21. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U.
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [Abstract] [Full Text] [Related]

  • 22. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 23. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B.
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [Abstract] [Full Text] [Related]

  • 24. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J.
    BMC Cancer; 2017 Jan 06; 17(1):27. PubMed ID: 28061764
    [Abstract] [Full Text] [Related]

  • 25. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 06; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
    Pal SK, Figlin RA.
    Target Oncol; 2011 Mar 06; 6(1):5-16. PubMed ID: 21484496
    [Abstract] [Full Text] [Related]

  • 30. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM.
    Clin Genitourin Cancer; 2007 Sep 06; 5(6):359-61. PubMed ID: 17956708
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M.
    J Oncol Pharm Pract; 2011 Sep 06; 17(3):274-8. PubMed ID: 20215482
    [Abstract] [Full Text] [Related]

  • 34. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE.
    Clin Genitourin Cancer; 2013 Jun 06; 11(2):115-20. PubMed ID: 23063578
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
    Roulin D, Demartines N, Dormond O.
    Biochem Soc Trans; 2011 Apr 06; 39(2):492-4. PubMed ID: 21428926
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Temsirolimus: a safety and efficacy review.
    Bukowski RM.
    Expert Opin Drug Saf; 2012 Sep 06; 11(5):861-79. PubMed ID: 22861825
    [Abstract] [Full Text] [Related]

  • 39. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM.
    Int J Cancer; 2014 May 15; 134(10):2322-9. PubMed ID: 24243565
    [Abstract] [Full Text] [Related]

  • 40. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
    Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM.
    BJU Int; 2014 Mar 15; 113(3):376-82. PubMed ID: 24053120
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.